New investigations into retatrutide, a dual stimulant for GLP-1 and GIP receptors, are revealing encouraging effects in treating obesity and related second-type disease. Preclinical data suggest a unique action https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/